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Background: The aim of this study was to examine the relative efficacy and safety of boceprevir 
and telaprevir, when used in combination with pegylated interferon alpha and ribavirin, using 
an indirect comparison meta-analysis.
Methods: Published phase II and phase III randomized placebo-controlled trials examining 
the efficacy of boceprevir and telaprevir in chronic hepatitis C virus genotype 1 infected adult 
populations were included. The primary outcomes were sustained virologic response, relapse, 
and discontinuation of all study drugs. Secondary outcomes included the adverse events of 
anemia, neutropenia, rash, and pruritus. 
Results: Four boceprevir trials and six telaprevir trials were included. No significant differences 
were observed for sustained virologic response among either naïve (relative risk [RR] 1.14, 
95% confidence interval [CI] 0.93–1.37, P = 0.20) or experienced patients (RR 0.81, 95% CI 
0.52–1.23, P = 0.30). Similarly, for relapse among naïve (RR 0.80, 95% CI 0.18–3.45, P = 0.77) 
and experienced patients (RR 1.71, 95% CI 0.90–3.24, P = 0.10), or discontinuation of therapy 
for naïve (RR 0.80, 95% CI 0.28–2.29, P = 0.72) and experienced patients (RR 0.88, 95% CI 
0.69–1.12, P = 0.30). Telaprevir was more likely to be associated with rash and pruritus, and 
boceprevir was more likely to be associated with neutropenia in certain patient populations.
Conclusion: Boceprevir and telaprevir appear comparable in terms of sustained virologic 
response, relapse, or discontinuation of therapy for patients treated with standard-dose therapy 
durations and response-guided therapy durations.
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Background
Two direct-acting antiviral compounds, boceprevir and telaprevir, have recently been 
approved by drug regulatory boards in North America and Europe to treat adults with 
chronic hepatitis C virus genotype 1 infection.1–3 Boceprevir and telaprevir prevent 
hepatitis C viral replication by inhibiting the activity of protease NS3/4A.4 Clinical 
trials demonstrate that boceprevir or telaprevir in combination with pegylated interferon 
(peginterferon) alpha and ribavirin dramatically improve treatment efficacy in both 
treatment-naïve patients (those who have not received any drug therapy for their 
hepatitis C virus infection)5–10 and treatment-experienced patients (those who have 
previously been treated for hepatitis C virus and did not achieve a sustained virologic 
response to the therapy),11–14 when compared to conventional peginterferon alpha and 
ribavirin therapy. Currently, there is no direct evidence to establish if boceprevir or 
telaprevir offer therapeutic advantages over one another. To this end, the relative efficacy 
and safety of boceprevir and telaprevir, when used in combination with peginterferon 
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alpha and ribavirin, were examined using a direct and indirect 
meta-analysis of the currently published evidence.
Methods
Eligibility criteria
Published phase II or phase III randomized placebo-controlled 
trials examining the efficacy and safety of boceprevir and 
telaprevir in hepatitis C virus genotype 1 infected adult 
populations were included. Trials had to include these direct-
acting drugs in addition to peginterferon alpha and ribavirin. 
No limitation on treatment duration was set. Therefore, 
trials could include standard dose-duration regimens (where 
boceprevir is provided in weeks 4–48 of a 48-week treatment 
duration or telaprevir is provided in weeks 1–12 of a 48-week 
treatment duration), response-guided therapy regimens, and 
any other treatment dose-duration regimens. Both treatment-
naïve and treatment-experienced populations were included. 
Trials that reported only on dosing strategies of the individual 
drugs without a comparison to a control were excluded.
Search strategy
In consultation with a medical librarian, a systematic 
search of the literature was conducted. Two broad and 
sensitive searches were conducted, one including only 
the term “boceprevir,” the other including only the term 
“telaprevir.” Each search was limited to clinical trials in 
humans. Searches were not limited by language, sex, or age. 
Two investigators (EM, ED) independently searched each 
of the following ten databases (from inception to week 40 
[October 3–9, 2011]): MEDLINE, Embase, Cochrane Central 
Register of Controlled Trials, AMED, CINAHL, TOXNET, 
Development and Reproductive Toxicology, Hazardous 
Substances Data Bank, PsycINFO, and Web of Science. 
The bibliographies of published systematic and narrative 
reviews and relevant included trials were also searched. 
Where necessary, industry was also contacted for assistance 
in identifying completed clinical trials.
Study selection
Two investigators (EM, ED) working independently, in 
duplicate, scanned all abstracts and obtained the full text 
reports of records indicating that the study was a randomized 
placebo-controlled trial that examined the efficacy and 
safety of boceprevir or telaprevir in adult populations. After 
obtaining full reports of the candidate studies, the same 
reviewers independently assessed eligibility via full text 
review. Where required, a third clinician reviewer (CC) 
provided arbitration.
Data abstraction and endpoints
Two investigators (EM, ED) working independently, in 
duplicate, abstracted data on the primary outcomes of interest: 
the proportion of patients achieving sustained virologic 
response (defined as an undetectable hepatitis C virus 
ribonucleic acid [RNA] at the end of the 24-week post therapy 
follow-up period), the proportion of patients relapsing (defined 
as a reoccurrence of hepatitis C virus RNA within the 24-week 
post therapy follow-up period), and the proportion of patients 
discontinuing treatment (defined as the discontinuation of all 
assigned study drugs during the set treatment period).
Outcomes data were extracted for both treatment-naïve 
patients (generally defined as patients with no exposure 
to peginterferon alpha plus ribavirin) and treatment-
experienced patients (generally defined as patients with 
prior exposure to peginterferon alpha plus ribavirin), and 
the subgroups of patients with compensated cirrhosis, 
prior relapse (generally defined as patients who had a full 
decrease in hepatitis C viral load after peginterferon alpha 
plus ribavirin treatment, but a subsequent reoccurrence of 
the virus during the 24-week follow-up period after the end 
of treatment), and prior nonresponse (generally defined as 
patients who did not achieve a decrease in hepatitis C viral 
load during peginterferon alpha plus ribavirin treatment or a 
partial decrease in hepatitis C viral load during peginterferon 
alpha plus ribavirin treatment). Data was also abstracted 
for commonly reported adverse events: anemia (generally 
defined as hemoglobin less than 100 g/L), neutropenia 
(generally defined as absolute neutrophil count less than 
0.75 109/L), rash (any, as reported by site investigators), and 
pruritus (any, as reported by site investigators). Furthermore, 
trial characteristics (ie, interventions, treatment doses, 
treatment durations) and participant baseline characteristics 
(ie, age, sex, genosubtype) were abstracted.
Data analysis
In order to assess interrater reliability on inclusion of articles, 
the phi statistic was calculated, which was first developed to 
provide a measure of interobserver agreement independent of 
chance.15 Pairwise meta-analysis of all trial evidence using a 
DerSimonian–Laird random effects model, which recognizes 
and anchors studies as a sample of all potential studies, and 
incorporates an additional between-study component to the 
estimate of variability, thus placing additional weighting 
on the smaller studies.16,17 When more than two trial arms 
could be pooled, heterogeneity in the pairwise estimates was 
assessed using the I2 statistic as a measure of the proportion 
of the overall variation that is attributable to between-study 
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heterogeneity.18 As there were no direct (head-to-head) 
evaluations of boceprevir versus telaprevir, the adjusted 
indirect comparison statistic, first described by Bucher et al,19 
was used. The adjusted indirect comparison utilized the 
evidence on boceprevir versus peginterferon plus ribavirin 
and the evidence on telaprevir versus peginterferon plus 
ribavirin to produce an estimate of comparative effectiveness 
between boceprevir and telaprevir. Meta-regression analysis 
of the indirect evidence was performed to explore whether the 
results from the indirect comparisons were robust to changes 
in the two trial baseline characteristics, type of peginterferon 
given (alpha-2a [peg-2a] or alpha-2b [peg-2b]), and treatment 
experience (naïve or experienced). Peginterferon type and 
treatment experience were included in the model for the 
primary meta-regression and each of the two covariates 
alone was included as a sensitivity analysis. For all analyses, 
relative risk was used as the primary effect estimate with 95% 
confidence intervals (CIs) for each.
As a sensitivity analysis, a Bayesian multiple treatment 
meta-analysis was applied.20 For treatment-naïve patients, 
four trials from a previous review21 that compared peg-2a with 
peg-2b were identified. To control for the fact that telaprevir 
had only been compared to peg-2a and boceprevir had only 
been compared to peg-2b among treatment-naïve patients, 
the comparison of peg-2a versus peg-2b was additionally 
included in the treatment network and a conventional 
random-effects multiple treatment comparison was carried 
out. For treatment-experienced patients, only one trial from 
a previous review that compared peg-2a with peg-2b was 
identified.21 With only one trial informing this comparison, 
and only one trial informing telaprevir versus peg-2a, it was 
not possible to run a Bayesian multiple treatment comparison. 
Therefore, a conventional frequentist adjusted indirect 
comparison including the peg-2a versus peg-2b comparison 
was performed.
The main analyses considered the three outcomes: 
sustained virologic response, relapse, and treatment 
discontinuation. The subgroup analyses used the same 
outcomes, where possible, but were restricted first to 
cirrhotic patients and then second to prior relapse and 
prior nonresponders. The adverse events analyses included 
anemia, neutropenia, rash, and pruritus as outcomes. Each 
analysis was conducted among two experimental settings: 
standard-dose duration (where boceprevir is provided in 
weeks 4–48 of a 48-week treatment duration or telaprevir 
is provided in weeks 1–12 of a 48-week treatment duration) 
and response-guided therapy, and was analyzed separately 
for treatment-naïve and treatment-experienced patients, 
with the exception of prior relapse and prior nonresponse 
patients who were all treatment-experienced. As a sensitivity 
analysis for the main analyses, all available boceprevir arms 
and telaprevir arms among naïve or experienced groups 
were examined. Analyses were conducted using StatsDirect 
version 2.5.2 (StatsDirect Ltd, Cheshire, United Kingdom) 
and R version 2.12.2.22
Results
Included studies
Ten published phase II and III randomized placebo-controlled 
trials provided efficacy and safety data among 5072 patients 
treated with boceprevir or telaprevir in combination with 
peginterferon alpha plus ribavirin. Interobserver agreement 
was very good (phi = 0.91). Four of the trials provided data 
among those treated with boceprevir and peginterferon alpha 
plus ribavirin combinations5,6,11,12 (two of these trials were 
conducted in treatment-naïve populations5,6 and two were 
conducted in treatment-experienced populations11,12) and six 
of the trials provided data among those treated with telaprevir 
and peginterferon alpha plus ribavirin combinations7–10,13,14 
(four of these trials were conducted in treatment-naïve popu-
lations7–10 and two were conducted in treatment-experienced 
populations13,14). Tables 1 and 2 provide the characteristics 
of these included trials. The populations were effectively 
comparable in terms of age, gender, and race. In terms of 
genosubtype, Kumada et al10 was an exception with a popula-
tion that was predominantly genosubtype 1b; genosubtype 
1a was most common among the populations recruited in 
all other trials. Fifteen trials identified in the search were 
excluded because they analyzed data from phase I trials,23–34 
or they were not placebo-controlled.35,36 Figure 1 shows a 
schematic of the study selection process.
Standard dose-duration boceprevir  
or telaprevir among all patients
All four randomized placebo-controlled boceprevir trials 
(two conducted among treatment-naïve patients and two 
conducted among treatment-experienced patients) included 
standard dose-duration trial arms,5,6,11,12 and three random-
ized placebo-controlled telaprevir trials (two conducted 
among treatment-naïve patients and one conducted among 
treatment-experienced patients) included standard dose-
duration trial arms.8,9,14
Tables 3 and 4 show the results of the direct comparison 
between standard dose-duration regimens of telaprevir or 
boceprevir coadministered with peginterferon alpha plus 
ribavirin (intervention) and placebo coadministered with 
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Boceprevir  Telaprevir 
17 publications identified and screened 
12 excluded 
–1 0 analyzed
data from phase
I trials 
–2  not placebo-
controlled
6 publications identified and screened 
3 excluded 
– Analyzed data
from phase I
trials
1 included 
– Publication in
press  
6 placebo-controlled trials included   4 placebo-controlled trials included  
1 included 
– Publication in
press  
Figure 1 Study flow diagram.
Table  3  Direct  comparison  of  the  proportion  of  patients  achieving  a  sustained  virologic  response,  relapsing  to  treatment,  or 
discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day during weeks 4–48 of 
a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Kwo et al6 77/103
70% (61%–77%)
39/104 
137/363
38% (33%  –42%) 1.91 (1.65–2.21)
  Poordad et al5 242/366
Experienced patients
  Bacon et al11 107/161
65% (60%–71%)
17/80 
14/67
21% (15%–28%) 3.09 (2.24–4.28)
  Flamm et al12 86/134
Relapse
Naïve patients
  Kwo et al6 2/81
6% (1%–14%)
12/53 
39/176
23% (17%–28%) 0.24 (0.06–1.00)
  Poordad et al5 24/265
Experienced patients
  Bacon et al11 14/121
12% (8%–17%)
8/25 
7/21
33% (21%  –47%) 0.36 (0.20–0.62)
  Flamm et al12 11/95
Discontinuation
Naïve patients
  Kwo et al6 27/103
34% (21%–49%)
52/104 
204/363
54% (49%–60%) 0.65 (0.47–0.89)
  Poordad et al5 151/366
Experienced patients
  Bacon et al11 55/161
37% (31%–44%)
55/80 
47/67
69% (61%–76%) 0.54 (0.45–0.65)
  Flamm et al12 55/134
Abbreviation: CI, confidence interval.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
110
Cooper et alTherapeutics and Clinical Risk Management 2012:8
Table  4  Direct  comparison  of  the  proportion  of  patients  achieving  a  sustained  virologic  response,  relapsing  to  treatment,  or 
discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day during weeks 1–12 of a 
48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 271/363
72% (65%–79%)
158/361
43%(39%  –48%) 1.69 (1.50–1.91)
  McHutchison et al9 53/79 31/75
Experienced patients
  Zeuzem et al14 171/266 64% (60%  –68%) 22/132 17%(13%  –22%) 3.86 (2.92–5.09)
Relapse
Naïve patients
  Jacobson et al8 27/314
8% (6%  –11%)
64/229
27% (22%  –33%) 0.30 (0.20–0.45)
  McHutchison et al9 3/51 8/35
Experienced patients
  Zeuzem et al14 26/204 13% (10%  –16%) 33/55 60% (51%  –69%) 0.21 (0.16–0.29)
Discontinuation
Naïve patients
  Jacobson et al8 80/363
26% (17%  –36%)
159/361
34% (15%  –55%) 0.81 (0.30–2.22)
  McHutchison et al9 25/79 17/75
Experienced patients
  Zeuzem et al14 100/266 38% (34%  –42%) 82/132 62% (56%  –68%) 0.61 (0.52–0.70)
Abbreviation: CI, confidence interval.
peginterferon alpha plus ribavirin (control). The results 
indicate that naïve and experienced patients treated with a 
standard dose-duration regimen of boceprevir or telaprevir 
in combination with peginterferon alpha plus ribavirin 
are generally more likely to achieve a sustained virologic 
response, less likely to relapse to treatment, and less likely to 
discontinue treatment when compared to those treated with 
peginterferon alpha plus ribavirin alone.
Table 5 shows the results of the indirect comparison 
between standard-dose duration regimens of boceprevir 
coadministered with peginterferon alpha plus ribavirin and 
standard-dose duration regimens of telaprevir coadministered 
with peginterferon alpha plus ribavirin. The results indicate 
that there are no differences between standard dose-duration 
regimens of boceprevir and telaprevir in terms of sustained 
virologic response, relapse to treatment, and discontinuation 
of treatment. Figures 2 and 3 graphically display results 
using a forest plot.
Response-guided durations that included 
boceprevir or telaprevir among all 
patients
Two randomized placebo-controlled boceprevir tri-
als (one conducted among treatment-naïve patients and 
one   conducted among treatment-experienced patients) 
included response-guided therapy arms,5,11 and one ran-
domized   placebo-controlled telaprevir trial (conducted 
among treatment-naïve patients) included response-guided 
therapy arms.8
Tables A and B in the Appendix show the results of 
the direct comparison between response-guided therapy 
regimens of telaprevir or boceprevir coadministered with 
peginterferon alpha plus ribavirin (intervention) and placebo 
coadministered with peginterferon alpha plus ribavirin (con-
trol). The results indicate that naïve and experienced patients 
receiving a response-guided therapy regimen consisting of 
boceprevir or telaprevir in combination with peginterferon 
alpha plus ribavirin are generally more likely to achieve 
a sustained virologic response, less likely to relapse to 
treatment, and less likely to discontinue treatment when 
compared to those treated with peginterferon alpha plus 
ribavirin alone.
Table 6 shows the results of the indirect comparison 
between response-guided therapy regimens of boceprevir 
coadministered with peginterferon alpha plus ribavirin and 
response-guided therapy regimens of telaprevir coadmin-
istered with peginterferon alpha plus ribavirin. The results 
indicate that there are no differences between boceprevir and 
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Sustained virologic response 1.14 (0.93, 1.37)
0.80 (0.18, 3.45)
0.80 (0.28, 2.29)
0.1 0.2 0.5 12 5
Relapse
Discontinuation
Favors
telaprevir
Favors
boceprevir
Figure 2 Forest plot of indirect comparison of standard dose-duration treatments in naïve patients addressing sustained virologic response, relapse, and discontinuation.
Table 5 Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, 
or discontinuing treatment in the standard dose-duration interventions boceprevir and telaprevir
Boceprevir Telaprevir Relative risk 
(95% CI)
P value
Sustained virologic response
Patients
  Naïve 1.91 (1.65–2.21) 1.69 (1.50–1.91) 1.14 (0.93–1.37) 0.20
  Experienced 3.09 (2.24–4.28) 3.86 (2.92–5.09) 0.81 (0.52–1.23) 0.30
Relapse
Patients
  Naïve 0.24 (0.06–1.00) 0.30 (0.20–0.45) 0.80 (0.18–3.45) 0.77
  Experienced 0.36 (0.20–0.62) 0.21 (0.16–0.29) 1.71 (0.90–3.24) 0.10
Discontinuation
Patients
  Naïve 0.65 (0.47–0.89) 0.81 (0.30–2.22) 0.80 (0.28–2.29) 0.72
  Experienced 0.54 (0.45–0.65) 0.61 (0.52–0.70) 0.88 (0.69–1.12) 0.30
Abbreviation: CI, confidence interval.
Sustained virologic response 0.81 (0.52, 1.23)
1.71 (0.90, 3.24)
0.88 (0.69, 1.12)
0.5 1 25
Relapse
Discontinuation
Favors
telaprevir
Favors
boceprevir
Figure 3 Forest plot of indirect comparison of standard dose-duration treatments in experienced patients addressing sustained virologic response, relapse, and discontinuation.
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Table 6 Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, 
or discontinuing treatment in the response-guided therapy interventions boceprevir and telaprevir
Boceprevir Telaprevir Relative risk (95% CI) P value
Sustained virologic response
Patients
  Naïve 1.69 (1.44–1.96) 1.71 (1.50–1.95) 1.00 (0.82–1.23) 0.87
  Experienced 2.76 (1.81–4.35) – – –
Relapse
Patients
  Naïve 0.42 (0.30–0.59) 0.32 (0.24–0.43) 1.31 (0.84–2.05) 0.25
  Experienced 0.48 (0.29–0.80) – – –
Discontinuation
Patients
  Naïve 0.67 (0.60–0.75) 0.62 (0.54–0.72) 1.08 (0.90–1.21) 0.60
  Experienced 0.47 (0.39–0.56) – – –
Abbreviation: CI, confidence interval.
telaprevir in terms of sustained virologic response, relapse to 
treatment, and discontinuation of treatment for naïve patients 
treated with a response-guided regimen. No trials included 
treatment-experienced patients treated with a response-
guided therapy regimen of telaprevir; and therefore, a com-
parison could not be made for this group. Figure 4 graphically 
displays the results using a forest plot.
Sensitivity analysis
All dose-durations of boceprevir or telaprevir  
among all patients
All four randomized placebo-controlled boceprevir 
trials5,6,11,12 and all six randomized placebo-controlled 
telaprevir trials7–10,13,14 contributed to the analysis of all dose-
durations combined.
Tables C–F in the Appendix show the results of the 
direct comparison between all dose-durations of telaprevir 
or boceprevir coadministered with peginterferon alpha plus 
ribavirin (intervention) and placebo coadministered with 
peginterferon alpha plus ribavirin (control). The results 
indicate that, in general, naïve and experienced patients 
treated with boceprevir or telaprevir in combination with 
peginterferon alpha plus ribavirin are more likely to achieve 
a sustained virologic response, less likely to relapse to 
treatment, and less likely to discontinue treatment when 
compared to those treated with peginterferon alpha plus 
ribavirin alone.
Indirect comparisons suggest that experienced patients 
treated with boceprevir at any point in a 48-week treatment 
course are more likely to relapse compared to experienced 
Sustained virologic response 1.00 (0.82, 1.23)
1.31 (0.84, 2.05)
1.08 (0.90, 1.21)
0.5 1 25
Relapse
Discontinuation
Favors
telaprevir
Favors
boceprevir
Figure 4 Forest plot of indirect comparison of response-guided therapy treatments in naïve patients addressing sustained virologic response, relapse, and discontinuation.
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patients treated with telaprevir (Table G, Appendix). 
However, closer inspection of the results reveals that this find-
ing is driven by a large absolute difference in relapse among 
the control arms rather than the treatment arms (Tables C and 
D, Appendix). No other differences were observed between 
boceprevir and telaprevir for all dose-durations (Tables G 
and H, Appendix).
Multiple treatment comparison
The multiple treatment comparison of the primary out-
come for naïve patients showed an almost identical result 
to the frequentist method (1.34, 95% creditable interval 
0.46–4.03). Given the sparseness of the network, it was not 
possible to apply a Bayesian approach to the experienced 
patients.
Meta-regression
For sustained virologic response, the meta-regression analysis 
of the indirect evidence demonstrated that the magnitude 
of effect significantly depends on whether patients are 
treatment-naïve or treatment-experienced (RR 1.96, 95% 
CI 1.60–2.42), but not the type of peginterferon alpha used 
(RR 1.12, 95% CI 0.84–1.55). Controlling for both variables, 
no significant difference was detected for boceprevir versus 
telaprevir (RR 1.12, 95% CI 0.82–1.52). For relapse, no 
significant difference was detected for treatment-naïve or 
treatment-experienced patients (RR 0.88, 95% CI 0.31–2.47) 
or type of peginterferon alpha (RR 0.79, 95% CI 0.17–3.70). 
Controlling for both variables, no significant difference was 
detected for boceprevir versus telaprevir (RR 0.80, 95% CI 
0.17–3.75). For discontinuation, no significant difference 
was detected for treatment-naïve or treatment-experienced 
patients (RR 0.76, 95% CI 0.36–1.61) or type of peginter-
feron alpha (RR 0.82, 95% CI 0.27–2.51). Controlling for 
both variables, no significant difference was detected for 
boceprevir versus telaprevir (RR 1.07, 95% CI 0.35–3.27). 
Sensitivity meta-regression analyses using only one covariate 
in the model yielded similar results to the model including 
both covariates.
Subgroups
Standard dose-durations of boceprevir or telaprevir 
among patients with compensated cirrhosis
All four randomized placebo-controlled boceprevir trials 
(two conducted among treatment-naïve patients and two 
conducted among treatment-experienced patients)5,6,11,12 
and two randomized placebo-controlled telaprevir trials 
(one conducted among treatment-naïve patients and one 
conducted among treatment-experienced patients)8,14 
included data on sustained virologic response among 
compensated cirrhosis patients treated with standard dose-
duration. Relapse and discontinuation data was not available 
for compensated cirrhosis patients treated with standard 
dose-durations.
Tables I and J in the Appendix show the results of 
the direct comparison between standard dose-duration 
regimens of telaprevir or boceprevir coadministered with 
peginterferon alpha plus ribavirin (intervention) and pla-
cebo coadministered with peginterferon alpha plus ribavirin 
(control) for patients with compensated cirrhosis. The 
results indicate that, in general, those treated with standard 
dose-duration boceprevir or telaprevir in combination with 
peginterferon alpha plus ribavirin are generally more likely 
to achieve a sustained virologic response when compared 
to those treated with peginterferon alpha plus ribavirin 
alone.
Table K in the Appendix shows the results of the indirect 
comparison between standard dose-duration regimens of 
boceprevir coadministered with peginterferon alpha plus 
ribavirin and standard dose-duration regimens of telaprevir 
coadministered with peginterferon alpha plus ribavirin for 
patients with compensated cirrhosis. The results show that 
there are no differences between standard dose-duration 
regimens of boceprevir and telaprevir among patients with 
compensated cirrhosis.
Response-guided therapy durations that included 
boceprevir or telaprevir among patients  
with compensated cirrhosis
Two randomized placebo-controlled boceprevir trials 
(one conducted among treatment-naïve patients and one 
conducted among treatment-experienced patients)5,11 
and one randomized placebo-controlled telaprevir trial 
(conducted among treatment-naïve patients)8 included data 
on sustained virologic response among compensated cirrhosis 
patients treated with a response-guided therapy duration. 
Relapse and discontinuation data were not available for 
compensated cirrhosis patients treated with a response-guided 
therapy duration.
Tables L and M in the Appendix show the results of 
the direct comparison between response-guided therapy 
regimens of telaprevir or boceprevir coadministered with 
peginterferon alpha plus ribavirin (intervention) and placebo 
coadministered with peginterferon alpha plus ribavirin 
(control) for patients with compensated cirrhosis. The 
results indicate that treatment-experienced patients with 
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compensated cirrhosis provided with a response-guided 
therapy regimen that included boceprevir in combination 
with peginterferon alpha plus ribavirin are more likely to 
achieve a sustained virologic response when compared to 
those treated with peginterferon alpha plus ribavirin alone. 
No telaprevir trial included data on treatment-experienced 
compensated cirrhosis patients provided with a response-
guided therapy regimen. No difference was observed between 
treatment-naïve compensated cirrhosis patients provided with 
a response-guided therapy regimen that included boceprevir 
or telaprevir in combination with peginterferon alpha plus 
ribavirin when compared to similar patients provided with 
peginterferon alpha plus ribavirin alone.
Table N in the Appendix shows the results of the indirect 
comparison between response-guided therapy regimens of 
boceprevir coadministered with peginterferon alpha plus 
ribavirin and response-guided therapy regimens of telaprevir 
coadministered with peginterferon alpha plus ribavirin for 
patients with compensated cirrhosis. The results indicate 
that there are no differences between response-guided 
therapy regimens including boceprevir and telaprevir among 
treatment-naïve patients with compensated cirrhosis.
Standard dose-durations of boceprevir or telaprevir 
among prior nonresponding and prior relapsing 
treatment-experienced patients
Both randomized placebo-controlled boceprevir trials con-
ducted among experienced patients11,12 and one randomized 
placebo-controlled telaprevir trial conducted among experi-
enced patients14 included sustained virologic response data 
stratified by prior nonresponding and prior relapsing patients 
for the standard-dose duration arms. Relapse and discontinu-
ation data were not available for prior nonresponding and 
prior relapsing patients.
Tables O and P in the Appendix show the results of the 
direct comparison between standard-dose duration regimens 
of telaprevir or boceprevir coadministered with peginterferon 
alpha plus ribavirin (intervention) and placebo coadminis-
tered with peginterferon alpha plus ribavirin (control) for 
prior nonresponding and prior relapsing patients. The results 
indicate that, in general, both prior nonresponding and 
relapsing patients treated with a standard-dose duration 
regimen of boceprevir or telaprevir in combination with 
peginterferon alpha plus ribavirin are more likely to achieve a 
sustained virologic response when compared to those treated 
with peginterferon alpha plus ribavirin alone.
Table Q in the Appendix shows the results of the indirect 
comparison between standard-dose duration regimens of 
boceprevir coadministered with peginterferon alpha plus 
ribavirin and standard-dose duration regimens of telaprevir 
coadministered with peginterferon alpha plus ribavirin for 
prior nonresponding and prior relapsing patients. The results 
show that there are no differences in terms of sustained viro-
logic response between boceprevir and telaprevir for prior 
nonresponding and prior relapsing patients.
Response-guided therapy durations that included 
boceprevir or telaprevir among prior nonresponding 
and prior relapsing treatment-experienced patients
One randomized placebo-controlled boceprevir trial con-
ducted among experienced patients11 included sustained 
virologic response data stratified for prior relapsing patients 
for a response-guided therapy arm. Data on prior nonre-
sponders was not available in this trial arm, nor was data on 
relapses and discontinuations. No telaprevir trial evaluated 
treatment-experienced patients treated with a response-
guided therapy regimen.
Table R in the Appendix shows the results of the direct 
comparison between response-guided therapy regimens of 
boceprevir coadministered with peginterferon alpha plus 
ribavirin (intervention) and placebo coadministered with 
peginterferon alpha plus ribavirin (control) for prior relaps-
ing patients. The results indicate that prior relapsing patients 
treated with boceprevir in combination with peginterferon 
alpha plus ribavirin are generally more likely to achieve a 
sustained virologic response when compared to those treated 
with peginterferon alpha plus ribavirin alone.
Adverse events
Adverse events among all patients treated with 
standard dose-duration boceprevir or telaprevir
All four randomized placebo-controlled boceprevir trials 
(two conducted among treatment-naïve patients and two con-
ducted among treatment-experienced patients) that included 
standard-dose duration arms5,6,11,12 and three randomized 
placebo-controlled telaprevir trials (two conducted among 
treatment-naïve patients and one conducted among treatment-
experienced patients) that included standard dose-duration 
arms8,9,14 provided adverse event data. Tables S and T in the 
Appendix show the results of the direct comparison between 
standard dose-duration regimens of telaprevir or boceprevir 
coadministered with peginterferon alpha plus ribavirin 
(intervention) and placebo coadministered with peginterferon 
alpha plus ribavirin (control).
Table 7 shows the results of the indirect comparison 
between standard-dose duration regimens of boceprevir 
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Table 7 Adjusted indirect comparison of adverse events between boceprevir and telaprevir standard dose-duration therapy interventions
Boceprevir Telaprevir Relative risk (95% CI) P value
Anemia
Patients
  Naïve 1.63 (1.39–1.92) 1.51 (0.88–2.61) 1.08 (0.61–1.90) 0.79
  Experienced 1.30 (0.42–4.03) 1.96 (1.43–2.68) 0.66 (0.21–2.14) 0.49
Neutropenia
Patients
  Naïve 1.51 (0.85–2.68) 0.81 (0.54–1.04) 1.86 (0.96–3.61) 0.06
  Experienced 0.86 (0.60–1.23) 1.35 (0.90–2.02) 0.64 (0.37–1.09) 0.10
Rash
Patients
  Naïve 1.05 (0.87–1.27) 1.49 (1.24–1.80) 0.70 (0.54–0.92) 0.01
  Experienced 1.99 (1.06–3.72) 1.97 (1.50–2.58) 1.01 (0.51–2.00) 0.98
Pruritus
Patients
  Naïve 0.95 (0.80–1.13) 1.41 (1.20–1.66) 0.67 (0.53–0.85) 0.001
  Experienced 1.10 (0.73–1.65) 1.90 (1.54–2.35) 0.58 (0.37–0.92) 0.02
Abbreviations: CI, confidence interval.
coadministered with peginterferon alpha plus ribavirin and 
standard-dose duration regimens of telaprevir coadministered 
with peginterferon alpha plus ribavirin. The results indicate 
that naïve patients treated with a standard-dose duration 
regimen of telaprevir in combination with peginterferon alpha 
plus ribavirin are more likely to develop a rash when com-
pared to those treated with a standard-dose duration regimen 
of boceprevir in combination with peginterferon alpha plus 
ribavirin. Furthermore, both naïve and experienced patients 
treated with a standard dose-duration regimen of telaprevir 
in combination with peginterferon alpha plus ribavirin are 
more likely to develop pruritus when compared to those 
treated with a standard dose-duration regimen of boceprevir 
in combination with peginterferon alpha plus ribavirin. No 
differences between boceprevir and telaprevir were observed 
for anemia and neutropenia.
Adverse events among all patients treated  
with response-guided therapy durations that 
included boceprevir or telaprevir
Two randomized placebo-controlled boceprevir trials (one 
conducted among treatment-naïve patients and one con-
ducted among treatment-experienced patients) that included 
response-guided therapy arms5,11 and one randomized 
placebo-controlled telaprevir trial (conducted among treat-
ment-naïve patients) that included a response guided therapy 
arm8 provided adverse event data.
Tables U and V in the Appendix show the results of 
the direct comparison between response-guided therapy 
regimens of boceprevir or telaprevir coadministered with 
peginterferon alpha plus ribavirin (intervention) and pla-
cebo coadministered with peginterferon alpha plus ribavirin 
(control).
Table 8 shows the results of the indirect comparison 
between response-guided therapy regimens of boceprevir 
coadministered with peginterferon alpha plus ribavirin and 
response-guided therapy regimens of telaprevir coadministered 
with peginterferon alpha plus ribavirin. The results indicate that 
naïve patients treated with a response-guided therapy regimen 
that included boceprevir in combination with peginterferon 
alpha plus ribavirin are more likely to develop neutropenia 
when compared to those treated with a response-guided 
therapy regimen that included telaprevir in combination with 
peginterferon alpha plus ribavirin. Furthermore, naïve patients 
treated with a response-guided therapy regimen that included 
telaprevir in combination with peginterferon alpha plus ribavi-
rin are more likely to develop rash or pruritus when compared 
to those treated with a response-guided therapy regimen that 
included boceprevir in combination with peginterferon alpha 
plus ribavirin. No differences were observed between boce-
previr and telaprevir for anemia.
Discussion
The results of the direct analysis indicate that patients pro-
vided a standard-dose duration or response-guided therapy 
duration of boceprevir or telaprevir in combination with 
peginterferon alpha plus ribavirin are generally more likely 
to achieve a sustained virologic response, less likely to 
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relapse to treatment, and less likely to discontinue treatment 
when compared with those treated with peginterferon plus 
ribavirin alone. The results of the indirect analysis indicate 
that there are no significant differences between boceprevir 
and telaprevir in terms of sustained virologic response, 
relapse, or discontinuation of therapy for patients treated 
with standard-dose duration or response-guided therapy 
duration. These findings were consistent in both treatment-
naïve and treatment-experienced study populations.
There are several issues to consider when interpreting the 
analysis. The authors are confident that all key studies were 
identified in the exhaustive search, and believe it unlikely 
that publication bias would exist in this high profile field. 
Good interobserver agreement was found between the 
included studies. The analysis used direct comparisons of 
telaprevir or boceprevir in combination with peginterferon 
alpha and ribavirin, as well as indirect comparisons of 
telaprevir and boceprevir in combination with peginterferon 
alpha and   ribavirin. The validity of indirect comparisons 
has received extensive research.37–43 However, it should 
be recognized that the strength of inference from indirect 
comparisons is limited by the inherent differences of the 
included studies.19 Some differences in the populations 
and methodology were found and addressed using meta-
regression and subgroup analyses, as discussed further below. 
Additionally, where possible, the I2 statistic was obtained and 
showed that in most cases there was little variation between 
studies, although heterogeneity tests are poorly powered, 
further supporting the use of indirect comparisons.
In the absence of direct evidence, the indirect comparison 
method is widely accepted by agencies such as the United 
Kingdom National Institute for Health and Clinical 
Excellence, the Canadian Drug Safety and Effectiveness 
Network, and the United States Agency for Healthcare 
Research and Quality. The largest evaluation of the 
consistency between direct and indirect comparisons of 
trials, published in 2011, found that there was a statistically 
significant inconsistency in only 14% of evaluations.40 
However, indirect comparisons may be underpowered to 
determine treatment differences, particularly when there is 
severe imbalance between the number of trials available for 
one treatment versus the other.44 The present study examined 
whether differences between treatments were significantly 
different in terms of a priori determined outcomes. The study 
did not determine whether the treatments were noninferior 
because noninferiority assumes that there is a reference 
drug.45 If the noninferiority margins were set as an upper CI 
of 0.8 and lower CI of 0.5 for sustained virologic response, 
then treatments appear to be noninferior.
There are certain trial level characteristics to consider. 
Telaprevir trials used a backbone therapy of predominantly 
peg-2a, while boceprevir trials used predominantly peg-
2b. Some studies have shown that peg-2a plus ribavirin is 
favorable over peg-2b plus ribavirin in terms of sustained 
virologic response.46,21 However, based on the results of the 
meta-regressions, this effect is minimal and should not have 
greatly influenced the outcomes in the present study. The 
weight-based ribavirin dosing strategy also differed between 
Table  8 Adjusted  indirect  comparison  of  adverse  events  between  boceprevir  and  telaprevir  response-guided  therapy  duration 
interventions
Boceprevir Telaprevir Relative risk (95% CI) P value
Anemia
Patients
  Naïve 1.68 (1.47–1.92) 1.96 (1.64–2.33) 0.86 (0.69–1.07) 0.17
  Experienced 2.16 (1.55–3.02) – – –
Neutropenia
Patients
  Naïve 1.18 (0.98–1.42) 0.81 (0.65–1.02) 1.46 (1.09–1.95) 0.05
Rash
Patients
  Naïve 1.11 (0.92–1.33) 1.48 (1.26–1.74) 0.75 (0.59–0.96) 0.02
  Experienced 3.33 (1.63–6.83) – – –
Pruritus
Patients
  Naïve 0.88 (0.73–1.04) 1.31 (1.16–1.48) 0.67 (0.54–0.83) 0.0003
  Experienced 1.06 (0.70–1.59) – – –
Abbreviation: CI, confidence interval.
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peg-2a and peg-2b; however, the level of detail necessary to 
control for this variable in the analysis was not available in 
the published literature.
The analysis of patients with compensated cirrhosis 
indicates that triple therapy including boceprevir or telapre-
vir is generally advantageous to conventional peginterferon 
alpha and ribavirin therapy in terms of sustained virologic 
response. However, the number of patients with compensated 
cirrhosis in the included studies was small, and the data 
reported on this subgroup were limited. Therefore,   drawing 
concrete conclusions regarding this treatment subgroup 
should be cautioned.
The analysis utilized the available data for treatment-
experienced patients, as presented in the trial publications, 
to examine sustained virologic response, relapse, and 
treatment discontinuation. A priori, it was known that 
most trials also presented separate data for prior relapsing 
and prior nonresponding treatment-experienced patients; 
and therefore, it was also possible to conduct analyses for 
these subgroups. However, there is a major limitation to 
this approach. The term nonresponder is typically used 
to refer to the combination of partial responders and null 
responders. However, the boceprevir trials, conducted 
among treatment-experienced patients, did not recruit null 
responders. In this regard, the treatment populations are 
dissimilar between the boceprevir and telaprevir trials, and 
the results of the analysis may underestimate the efficacy 
of telaprevir and/or overestimate the efficacy of boceprevir 
in the prior nonresponse subgroup of patients. In spite of this, 
in nontrial clinical practice, the history of prior on-treatment 
virologic response to treatment is often incomplete or missing 
altogether. Therefore, composite estimates for treatment-
experienced patients, as provided by the present analysis, 
may be of clinical utility.
The analysis of adverse events indicated that skin 
conditions, such as rash and pruritus were more common in 
those treated with boceprevir or telaprevir in combination 
with peginterferon alpha plus ribavirin than peginterferon 
alpha plus ribavirin alone. The indirect analysis indicates 
that these conditions were more likely to occur with those 
taking telaprevir than boceprevir. The primary concern 
related to the dermatological complications of telaprevir 
is that of severe rash, and in rare cases, Stevens–Johnson 
syndrome.47
Cytopenias are a well-recognized side effect of peginter-
feron alpha and ribavirin therapy. The analysis showed that 
both boceprevir and telaprevir generally appear to exacerbate 
such conditions. Indirect analyses comparing boceprevir 
and telaprevir found that neutropenia is more likely to occur 
in boceprevir recipients provided with a response-guided 
therapy regimen. However, there is little, if any, clinical 
consequence with treatment-induced neutropenia in terms 
of infectious diseases complication risk.48
In conclusion, no significant differences were found 
between the two direct-acting agents in terms of major clini-
cal endpoints. Adverse event profiles differ between agents 
and are key variables that clinicians and patients will consider 
when selecting a protease inhibitor. Recognizing that indirect 
estimates are best estimates in the absence of direct (head-
to-head) evaluations, the authors believe that the present 
study has implications for clinicians in terms of choosing the 
most effective and most tolerable direct-acting agent.
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Appendix
Table A Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or 
discontinuing treatment in the trial intervention (response-guided therapy duration boceprevir) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Poordad et al5 233/368 63% (60%–67%) 137/363 38% (34%–41%) 1.69 (1.44–1.96)
Experienced patients
  Bacon et al11 95/162 59% (53%–64%) 17/80 22% (16%–28%) 2.76 (1.81–4.35)
Relapse
Naïve patients
  Poordad et al5 24/257 9% (7%–12%) 39/176 22% (18%–27%) 0.42 (0.30–0.59)
Experienced patients
  Bacon et al11 17/111 16% (11%–21%) 8/25 33% (21%–46%) 0.48 (0.29–0.80)
Discontinuation
Naïve patients
  Poordad et al5 139/368 38% (34%–41%) 204/363 56% (53%–60%) 0.67 (0.60–0.75)
Experienced patients
  Bacon et al11 52/162 32% (27%–37%) 55/80 69% (61%–75%) 0.47 (0.39–0.56)
Abbreviation: CI, confidence interval.
Table B Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or 
discontinuing treatment in the trial intervention (response-guided therapy duration telaprevir) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 271/363
72% (66%–77%) 158/361 44% (40%–47%) 1.71 (1.50–1.95)
250/364
Relapse
Naïve patients
  Jacobson et al8 27/314
9% (7%–12%) 64/229 28% (24%–32%) 0.32 (0.24–0.43)
28/295
Discontinuation
Naïve patients
  Jacobson et al8 95/363
27% (24%–31%) 159/361 44% (40%–48%) 0.62 (0.54–0.72)
104/364
Abbreviation: CI, confidence interval.
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Table C Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or 
discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day at any point during a 
48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk (95% CI) 
(I2 [95% CI]) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Kwo et al6 77/103
62% (53%–69%)
39/104
38% (33%–42%)
1.65 (1.43–1.91) 
(48.1% [0%–77.7%])
69/103
8/16
21/59
  Poordad et al5 242/366
137/363
233/368
Experienced patients
  Bacon et al11 107/161
63% (58%–68%)
17/80
21% (15%–28%)
2.98 (2.29–3.87) 
(0% [0%–72.9%])
95/162
  Flamm et al12 86/134 14/67
Relapse
Naïve patients
  Kwo et al6 2/81
9% (6%–12%)
12/53
23% (17%–28%)
0.42 (0.28–0.61) 
(31.7% [0%–72.2%])
5/76
1/9
6/28
  Poordad et al5 24/265
39/176
24/257
Experienced patients
  Bacon et al11 14/121
13% (10%–17%)
8/25
33% (21%–47%)
0.40 (0.26–0.62) 
(0% [0%–72.9%])
17/111
  Flamm et al12 11/95 7/21
Discontinuation
Naïve patients
  Kwo et al6 27/103
39% (34%–45%)
52/104
54% (49%–60%)
0.75 (0.64–0.88) 
(54.1% [0%–79.7%])
40/103
8/16
31/59
  Poordad et al5 151/366
204/363
139/368
Experienced patients
  Bacon et al11 55/161
36% (31%–41%)
55/80
69% (61%–76%)
0.52 (0.44–0.60) 
(0% [0%–72.8%])
52/162
  Flamm et al12 55/134 47/67
Abbreviation: CI, confidence interval.
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Table D Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or 
discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day at any point during a 
48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched placebo 
coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk (95% CI) 
(I2 [95% CI]) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 271/363
71% (66%–75%)
158/361
43% (39%–48%)
1.64 (1.50–1.79) 
(0% [0%–72.9%])
250/364
  McHutchison et al9 53/79 31/75
Experienced patients
  Zeuzem et al14 171/266
62% (55%–69%)
22/132
16% (11%–20%)
3.88 (3.05–4.94) 
(0% [0%–72.9%])
175/264
  McHutchison et al13 60/113 16/114
Relapse
Naïve patients
  Jacobson et al8 27/314
9% (7%–11%)
64/229
29% (24%–35%)
0.30 (0.22–0.39) 
(0% [0%–72.9%])
28/295
  McHutchison et al9 3/51 8/35
Experienced patients
  Zeuzem et al14 27/210
13% (10%–16%)
33/55
58% (50%–66%)
0.22 (0.17–0.29) 
(0% [0%–72.9%])
26/204
  McHutchison et al13 10/76 18/34
Discontinuation
Naïve patients
  Jacobson et al8 80/363
27% (21%–32%)
159/361
34% (15%–55%)
0.75 (0.45–1.23) 
(84.3% [15.5%–93.0%])
104/364
  McHutchison et al9 25/79 17/75
Experienced patients
  Zeuzem et al14 100/266
39% (29%–50%)
82/132
65% (59%–71%)
0.60 (0.47–0.77) 
(73.7% [0%–90.0%])
79/264
  McHutchison et al13 58/113 78/114
Abbreviations: CI, confidence interval.
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Table E Direct comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, or 
discontinuing treatment in the trial intervention (boceprevir provided at a dose of 800 mg three times per day at any point during 
a 12–48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched 
placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk (95% CI) 
(I2 [95% CI]) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Kwo et al6 77/103
60% (53%–67%)
39/104
38% (33%–42%)
1.62 (1.45–1.82) 
(36.6% [0%–70.8%])
69/103
8/16
21/59
58/103
58/107
  Poordad et al5 242/366
137/363
233/368
Relapse
Naïve patients
  Kwo et al6 2/81
13% (8%–20%)
12/53
23% (17%–28%)
0.55 (0.35–0.88) 
(67.5% [9.6%–82.8%])
5/76
1/9
6/28
18/79
24/84
  Poordad et al5 24/265
39/176
24/257
Discontinuation
Naïve patients
  Kwo et al6 27/103
36% (31%–42%)
52/104
54% (49%–60%)
0.70 (0.61–0.82) 
(54.9% [0%–77.8%])
40/103
8/16
31/59
27/103
30/107
  Poordad et al5 151/366
204/363
139/368
Abbreviation: CI, confidence interval.
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Table F  Direct  comparison of the  proportion  of patients achieving  a sustained  virologic response, relapsing to treatment,  or 
discontinuing treatment in the trial intervention (telaprevir provided at a dose of 750 mg three times per day at any point during 
a 12–48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial control (matched 
placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk (95% CI) 
(I2 [95% CI]) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 271/363
67% (62%–72%)
158/361
44% (41%–47%)
1.57 (1.45–1.69) 
(0% [0%–56.3%])
250/364
  McHutchison et al9 53/79
31/75 48/79
6/17
  Hezode et al7 49/82
38/82
56/81
  Kumada et al10 92/126 31/63
Experienced patients
  Zeuzem et al14 171/266
60% (52%–67%)
22/132
16% (11%–20%)
3.84 (3.09–4.76) 
(0% [0%–67.9%])
175/264
  McHutchison et al13 60/113
16/114
59/115
Relapse
Naïve patients
  Jacobson et al8 27/314
13% (8%–18%)
64/229
26% (22%–31%)
0.53 (0.32–0.88) 
(73% [31.9%–85.1%])
28/295
  McHutchison et al9 3/51
8/35 1/41
3/9
  Hezode et al7 19/63
10/45
8/57
  Kumada et al10 20/117 11/49
Experienced patients
  Zeuzem et al14 27/210
17% (10%–24%)
33/55
57% (50%–64%)
0.28 (0.17–0.46) 
(76.3% [0%–89.4%])
26/204
  McHutchison et al13 10/76
18/34
26/87
Discontinuation
Naïve patients
  Jacobson et al8 95/363
28% (22%–34%)
159/361
33% (27%–40%)
0.86 (0.61–1.22) 
(84.8% [69.9%–90.5%])
104/364
  McHutchison et al9 25/79
17/75 37/79
8/17
  Hezode et al7 10/82
32/82
20/81
  Kumada et al10 27/126 17/63
Experienced patients
  Zeuzem et al14 100/266
36% (27%–45%)
82/132
65% (59%–71%)
0.54 (0.41–0.71) 
(80.4% [19.7%–90.7%])
79/264
  McHutchison et al13 58/113
78/114
29/115
Abbreviation: CI, confidence interval.
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Table G Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, 
or discontinuing treatment at any point in a 48-week treatment course using boceprevir or telaprevir
Boceprevir Telaprevir Relative risk 
(95% CI)
P value
Sustained virologic response
Patients
  Naïve 1.65 (1.43–1.91) 1.64 (1.50–1.79) 1.01 (0.85–1.19) 0.94
  Experienced 2.98 (2.29–3.87) 3.88 (3.05–4.94) 0.77 (0.54–1.10) 0.15
Relapse
Patients
  Naïve 0.42 (0.28–0.61) 0.30 (0.22–0.39) 1.40 (0.86–2.28) 0.18
  Experienced 0.40 (0.26–0.62) 0.22 (0.17–0.29) 1.82 (1.09–3.03) 0.02
Discontinuation 
Patients
  Naïve 0.75 (0.64–0.88) 0.75 (0.45–1.23) 1.00 (0.59–1.69) 1.00
  Experienced 0.52 (0.44–0.60) 0.60 (0.47–0.77) 0.87 (0.65–1.16) 0.34
Abbreviation: CI, confidence interval.
Table H Adjusted indirect comparison of the proportion of patients achieving a sustained virologic response, relapsing to treatment, 
or discontinuing treatment at any point in a 12–48-week treatment course using boceprevir or telaprevir
Boceprevir Telaprevir Relative risk  
(95% CI)
P value
Sustained virologic response
Patients
  Naïve 1.62 (1.45–1.82) 1.57 (1.45–1.69) 1.06 (0.92–1.21) 0.41
  Experienced 2.98 (2.29–3.87) 3.84 (3.09–4.76) 0.78 (0.55–1.09) 0.14
Relapse
Patients
  Naïve 0.55 (0.35–0.88) 0.53 (0.32–0.88) 1.04 (0.52–2.06) 0.91
  Experienced 0.40 (0.26–0.62) 0.28 (0.17–0.46) 1.43 (0.74–2.77) 0.29
Discontinuation
Patients
  Naïve 0.70 (0.61–0.82) 0.86 (0.61–1.22) 0.81 (0.56–1.19) 0.28
  Experienced 0.52 (0.44–0.60) 0.54 (0.41–0.71) 0.96 (0.70–1.32) 0.81
Abbreviation: CI, confidence interval.
Table I Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (boceprevir 
provided at a dose of 800 mg three times per day during weeks 4–48 of a 48-week treatment course and coadministered with pegylated 
interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 
48 weeks) among patients with compensated cirrhosis
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Kwo et al6 3/6
44% (27%–61%)
2/8
39% (20%–59%) 1.07 (0.55–2.09)
  Poordad et al5 10/24 6/13
Experienced patients
  Bacon et al11 17/22
63% (37%–86%)
0/10
5% (0.1%–7%) 6.91 (1.46–32.61)
  Flamm et al12 12/24 1/9
Abbreviation: CI, confidence interval.
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Table J Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (telaprevir 
provided at a dose of 750 mg three times per day during weeks 1–12 of a 48-week treatment course and coadministered with pegylated 
interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 
48 weeks) among patients with compensated cirrhosis
Trial Intervention Control Relative risk  
(95% CI)
N
Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 13/21 61% (47%–75%) 7/21 34% (21%–49%) 1.86 (1.14–3.03)
Experienced patients
  Zeuzem et al14 77/119 65% (58%–71%) 6/59 11% (6%–17%) 6.36 (3.69–10.97)
Abbreviation: CI, confidence interval.
Table K Adjusted indirect comparison of the proportion of compensated cirrhosis patients achieving a sustained virologic response 
in the boceprevir and telaprevir standard-dose durations
Patients
Boceprevir Telaprevir
Relative risk 
(95% CI)
P value
Sustained virologic response
Naive 1.07 (0.55–2.09) 1.86 (1.14–3.03) 1.73 (0.70–4.28) 0.33
Experienced 6.91 (1.46–32.61) 5.84 (3.25–10.50) 0.84 (0.16–4.44) 0.36
Abbreviation: CI, confidence interval.
Table L Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (response-
guided therapy duration boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus 
ribavirin) among patients with compensated cirrhosis
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Poordad et al5 5/16 31% (11%–59%) 6/13 46% (19%–75%) 0.68 (0.27–1.70)
Experienced patients
  Bacon et al11 6/17 35% (14%–62%) 0/10 0% 7.41 (1.04–52.94)
Abbreviation: CI, confidence interval.
Table M Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (response-
guided therapy duration telaprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin) 
among patients with compensated cirrhosis
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Naïve patients
  Jacobson et al8 13/21
51% (33%–69%)
7/21
33% (15%–57%) 1.56 (0.94–2.60)
11/26
Abbreviation: CI, confidence interval.
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Table N Adjusted indirect comparison of the proportion of compensated cirrhosis patients achieving a sustained virologic response 
in the boceprevir and telaprevir response-guided therapy durations
Patients Boceprevir Telaprevir Relative risk 
(95% CI)
P value
Sustained virologic response
Naive 0.68 (0.27–1.70) 1.56 (0.94–2.60) 0.44 (0.15–1.25) 0.12
Experienced 7.41 (1.04–52.94) – – –
Abbreviation: CI, confidence interval.
Table O Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (boceprevir 
provided at a dose of 800 mg three times per day during weeks 4–48 of a 48-week treatment course and coadministered with pegylated 
interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 
48 weeks) among prior nonresponding and relapsing treatment-experienced patients
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Prior nonresponders
  Bacon et al11 30/58
50% (40%–60%)
2/29
8% (2%–17%) 8.09 (2.66–24.65)
  Flamm et al12 17/36 1/20
Prior relapsers
  Bacon et al11 77/103
72% (66%–78%)
15/51
29% (21%–38%) 2.54 (1.84–3.52)
  Flamm et al12 69/98 13/47
Abbreviation: CI, confidence interval.
Table P Direct comparison of the proportion of patients achieving sustained virologic response in the trial intervention (telaprevir 
provided at a dose of 800 mg three times per day during weeks 1–12 of a 48-week treatment course and coadministered with pegylated 
interferon alpha plus ribavirin) and the trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 
48 weeks) among prior nonresponding and relapsing treatment-experienced patients
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Prior nonresponders
  Zeuzem et al14 50/121 41% (35%–48%) 6/64 10% (5%–16%) 4.41 (2.52–7.71)
Prior relapsers
  Zeuzem et al14 121/145 83% (79%–87%) 16/68 24% (17%–31%) 3.55 (2.61–4.82)
Abbreviation: CI, confidence interval.
Table Q Adjusted indirect comparison of the proportion of prior nonresponding and prior relapsing patients achieving a sustained 
virologic response in the boceprevir and telaprevir standard-dose durations
Patients Boceprevir Telaprevir Relative risk 
(95% CI)
P value
Sustained virologic response
Prior nonresponders 8.09 (2.66–24.65) 4.41 (2.52–7.71) 0.54 (0.15–1.89) 0.33
Prior relapsers 2.54 (1.84–3.52) 3.55 (2.61–4.82) 0.71 (0.45–1.11) 0.14
Abbreviation: CI, confidence interval.
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Table R Direct comparison of the proportion of patients achieving sustained virologic response in the response guided therapy trial 
intervention (response-guided boceprevir) and the trial control (matched placebo coadministered with pegylated interferon alpha plus 
ribavirin for 48 weeks) among prior relapsing treatment-experienced patients
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Sustained virologic response
Prior relapsers
  Bacon et al11 23/57 40% (28%–54%) 2/29 7% (0%–23%)  5.85 (1.75–21.71)
Abbreviation: CI, confidence interval.
Table S Direct comparison of adverse events between the trial intervention (boceprevir provided at a dose of 800 mg three times per 
day during weeks 4–48 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial 
control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Anemia
Naïve patients
  Kwo et al6 54/103
50% (45%–54%)
35/104
30% (26%–35%) 1.63 (1.39–1.92)
  Poordad et al5 179/366 107/363
Experienced patients
  Bacon et al11 74/161
42% (34%–50%)
16/80
34% (10%–64%) 1.30 (0.42–4.03)
  Flamm et al12 50/134 33/67
Neutropenia
Naïve patients
  Kwo et al6 26/103
25% (22%–30%)
12/104
17% (9%–27%) 1.51 (0.85–2.68)
  Poordad et al5 93/366 77/363
Experienced patients
  Flamm et al12 31/134 23% (18%–29%) 18/67 27% (20%–35%) 0.86 (0.60–1.23)
Rash
Naïve patients
  Poordad et al5 88/366 24% (21%–27%) 83/363 23% (20%–26%) 1.05 (0.87–1.27)
Experienced patients
  Bacon et al11 22/161
15% (12%–20%)
4/80
8% (3%–14%) 1.99 (1.06–3.72)
  Flamm et al12 23/134 7/67
Pruritus
Naïve patients
  Poordad et al5 94/366 26% (23%–29%) 98/363 27% (24%–30%) 0.95 (0.80–1.13)
Experienced patients
  Bacon et al11 31/161 19% (15%–24%) 14/80 18% (12%–24%) 1.10 (0.73–1.65)
Abbreviation: CI, confidence interval.
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Table T Direct comparison of adverse events between the trial intervention (telaprevir provided at a dose of 750 mg three times per 
day during weeks 1–12 of a 48-week treatment course and coadministered with pegylated interferon alpha plus ribavirin) and the trial 
control (matched placebo coadministered with pegylated interferon alpha plus ribavirin for 48 weeks)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Anemia
Naïve patients
  Jacobson et al8 135/363
35% (28%–42%)
70/361
22% (15%–29%) 1.51 (0.88–2.61)
  McHutchison et al9 23/79 20/75
Experienced patients
  Zeuzem et al14 79/266 30% (26%–34%) 20/132 15% (11%–20%) 1.96 (1.43–2.68)
Neutropenia
Naïve patients
  Jacobson et al8 51/363
18% (10%–29%)
68/361
20% (16%–24%) 0.81 (0.54–1.04)
  McHutchison et al9 19/79 18/75
Experienced patients
  Zeuzem et al14 38/266 14% (12%–18%) 14/132 11% (7%–15%) 1.35 (0.90–2.02)
Rash
Naïve patients
  Jacobson et al8 133/363
48% (26%–71%)
88/361
32% (17%–49%) 1.49 (1.24–1.80)
  McHutchison et al9 48/79 31/75
Experienced patients
  Zeuzem et al14 99/266 37% (33%–41%) 25/132 19% (15%–24%) 1.97 (1.50–2.58)
Pruritus
Naïve patients
  Jacobson et al8 181/363
47% (38%–55%)
131/361
30% (18%–44%) 1.41 (1.20–1.66)
  McHutchison et al9 32/79 17/75
Experienced patients
  Zeuzem et al14 138/266 52% (48%–56%) 36/132 27% (22%–33%) 1.90 (1.54–2.35)
Abbreviation: CI, confidence interval.
Table U Direct comparison of adverse events between the trial intervention (response-guided therapy duration boceprevir) and the 
trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Anemia
Naïve patients
  Poordad et al5 182/368 49% (46%–53%) 107/363 30% (26%–33%) 1.68 (1.47–1.92)
Experienced patients
  Bacon et al11 70/162 43% (38%–49%) 16/80 20% (15%–27%) 2.16 (1.55–3.02)
Neutropenia
Naïve patients
  Poordad et al5 92/368 25% (22%–28%) 77/363 21% (18%–24%) 1.18 (0.98–1.42)
Rash
Naïve patients
  Poordad et al5 93/368 25% (22%–29%) 83/363 23% (20%–26%) 1.11 (0.92–1.33)
Experienced patients
  Bacon et al11 27/162 17% (13%–21%) 4/80 6% (3%–10%) 3.33 (1.63–6.83)
Pruritus
Naïve patients
  Poordad et al5 87/368 24% (21%–27%) 98/363 27% (24%–30%) 0.88 (0.73–1.04)
Experienced patients
  Bacon et al11 30/162 19% (15%–23%) 14/80 18% (12%–24%) 1.06 (0.70–1.59)
Abbreviation: CI, confidence interval.
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Table V Direct comparison of adverse events between the trial intervention (response-guided therapy duration telaprevir) and the 
trial control (matched placebo coadministered with pegylated interferon alpha plus ribavirin)
Trial Intervention Control Relative risk  
(95% CI) N Pooled 
(95% CI)
N Pooled 
(95% CI)
Anemia
Naïve patients
  Jacobson et al8 135/363
38% (35%–42%) 70/361 19% (17%–22%) 1.96 (1.64–2.33)
141/364
Neutropenia
Naïve patients
  Jacobson et al8 51/363
16% (13%–19%) 69/361 19% (16%–22%) 0.81 (0.65–1.02)
62/364
Rash
Naïve patients
  Jacobson et al8 133/363
36% (33%–40%) 88/361 24% (21%–28%) 1.48 (1.26–1.74)
129/364
Pruritus
Naïve patients
  Jacobson et al8 181/363
48% (43%–52%) 131/361 36% (33%–40%) 1.31 (1.16–1.48)
165/364
Abbreviation: CI, confidence interval.
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